Specify a stock or a cryptocurrency in the search bar to get a summary
Haleon PLC
HLNCFHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom. Address: The Heights, Weybridge, United Kingdom, KT13 0NY
Analytics
WallStreet Target Price
28 002.45 GBXP/E ratio
33.05Dividend Yield
1.56 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HLNCF
Dividend Analytics HLNCF
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
3676 %Dividend History HLNCF
Stock Valuation HLNCF
Financials HLNCF
Results | 2019 | Dynamics |